New shot aims to tame hepatitis b without daily pills
NCT ID NCT07654283
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This phase 2 trial tests an experimental drug called AHB-137 in 70 adults with chronic hepatitis B who are already on antiviral pills. The drug is given as a shot under the skin. The goal is to see if it can lower the virus to undetectable levels and allow some people to stop their daily medication. The study is open-label, meaning everyone knows they are getting the drug, and it is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AHB-137 (an experimental drug given as a shot under the skin)
- What this could lead to
- If successful, this could point toward a new way to help people with chronic hepatitis B stop their daily antiviral pills and keep the virus under control.
- What could go wrong
- This is an early phase 2 trial with only 70 people, so results may not apply to everyone. The drug may not work as hoped, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B CHRONIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Clinica Mangiagalli
NOT_YET_RECRUITINGMilan, Milan, 20122, Italy
-
Hôpital Beaujon
NOT_YET_RECRUITINGClichy, 92118, France
-
King's College Hospital
NOT_YET_RECRUITINGLondon, London, SE5 9RS, United Kingdom
-
NYU Langone Health
NOT_YET_RECRUITINGNew York, New York, 10016, United States
-
Stanford University
NOT_YET_RECRUITINGPalo Alto, California, 94304-1509, United States
-
Texas Liver Institute
RECRUITINGSan Antonio, Texas, 78215-2100, United States
-
University of Calgary
NOT_YET_RECRUITINGCalgary, Alberta, T2N 4N1, Canada
-
University of Maryland
NOT_YET_RECRUITINGBaltimore, Maryland, 21201-1009, United States
-
Vall d'Hebron Hospital
NOT_YET_RECRUITINGBarcelona, Barcelona, 8035, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Can a Two-Drug combo finally beat chronic hepatitis b?
- Stick-On ultrasound patch could spot liver damage without a specialist
- Experimental drug aims for functional cure in hepatitis b
- 10-Year hepatitis study aims to unlock secrets of liver disease
- New injection aims to tame chronic hepatitis b